Lexaria Bioscience Secures $4 Million in Capital Through Registered Direct Offering

Lexaria Bioscience Corp. has entered into a definitive agreement for a $4 million registered direct offering, marking a significant financial milestone for the drug delivery technology company. The offering involves the sale of 2,666,667 shares of common stock at $1.50 per share, priced at-the-market under Nasdaq rules. This capital infusion comes at a critical time for the company as it continues to develop its proprietary DehydraTECH technology platform.

The importance of this financing extends beyond the immediate financial boost. For a biotechnology company like Lexaria, which specializes in improving drug delivery methods, consistent funding is essential for ongoing research and development activities. The company's DehydraTECH platform represents a potentially transformative approach to oral drug delivery, with demonstrated abilities to enhance bio-absorption and improve drug effectiveness. The $4 million in gross proceeds, before deducting placement agent fees and other expenses, will be allocated toward working capital and general corporate purposes, ensuring the company can maintain its operational momentum.

H.C. Wainwright & Co. is serving as the exclusive placement agent for this offering, which includes a concurrent private placement component. In addition to the common stock offering, Lexaria will issue unregistered warrants to purchase up to 2,666,667 shares of common stock at an exercise price of $1.37 per share. These warrants are immediately exercisable and will expire five years from the effective date of the resale registration statement. The offering structure demonstrates sophisticated financial planning, with the common stock portion being conducted under an effective shelf registration statement filed with the Securities and Exchange Commission. Investors can access detailed offering documents through the SEC's website where the prospectus supplement and accompanying prospectus will be available.

The timing of this offering, scheduled to close around September 29, 2025, reflects strategic financial management during a period when biotechnology companies face increasing pressure to secure adequate funding for research initiatives. Lexaria's ability to successfully execute this offering signals investor confidence in both the company's technology and its management team. The DehydraTECH platform's potential applications across various drug categories position Lexaria to potentially capture significant market share in the evolving drug delivery sector. Additional information about the company's technology and research can be found on their corporate website at www.lexariabioscience.com.

This capital raise occurs against the backdrop of increasing regulatory scrutiny and scientific advancement in drug delivery technologies. The funding will enable Lexaria to continue its research efforts while navigating the complex patent application and approval processes essential for protecting its intellectual property portfolio. With 50 patents already granted and additional patents pending worldwide, the company's technology represents substantial long-term value potential. The successful completion of this offering underscores the market's recognition of Lexaria's position as an innovator in pharmaceutical delivery systems.